Banco Santander S.A. Sells 63,587 Shares of Novo Nordisk A/S $NVO

Banco Santander S.A. cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 42.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 84,567 shares of the company’s stock after selling 63,587 shares during the quarter. Banco Santander S.A.’s holdings in Novo Nordisk A/S were worth $4,693,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Lockheed Martin Investment Management Co. raised its holdings in shares of Novo Nordisk A/S by 179.4% in the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after purchasing an additional 27,900 shares during the period. Martin Capital Partners LLC increased its position in Novo Nordisk A/S by 53.8% in the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after buying an additional 41,129 shares during the last quarter. Clifford Swan Investment Counsel LLC increased its position in Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after buying an additional 37,453 shares during the last quarter. Markel Group Inc. raised its stake in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $1,294,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, Citigroup started coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Large Vivtex collaboration expands Novo’s push into oral obesity/diabetes medicines, which could widen patient access and reduce dependency on injectables — a long‑term growth signal. Novo Nordisk Pipelines Oral Obesity Drugs
• Positive Sentiment: Strong phase‑2 China data for triple‑agonist UBT251 (nearly ~20% weight loss reported) supports Novo’s broader pipeline beyond GLP‑1 and bolsters future product optionality. China UBT251 Trial
• Positive Sentiment: Several bullish commentary pieces argue the sell‑off overstates fundamental damage: oral Wegovy adoption and expanded Medicare coverage are cited as durable demand drivers and cash‑flow support. Why I’m Still Bullish On Novo
• Neutral Sentiment: Short interest fell meaningfully in February, reducing one immediate source of potential downside pressure (fewer forced covers), but overall market sentiment remains mixed.
• Neutral Sentiment: Broader market rotation into defensive names and sector dynamics are influencing trading — Novo’s large market cap and dividend yield make it sensitive to flows unrelated to biotech fundamentals.
• Negative Sentiment: Multiple analyst downgrades and lowered price targets this week prompted selling and contributed directly to intraday weakness; investors are focused on near‑term U.S. price compression and margin implications. Analyst Downgrade — American Banking News
• Negative Sentiment: Pomerantz law‑firm investor alert / investigation increases legal risk and uncertainty for shareholders, which typically depresses sentiment until clarity arrives. Pomerantz Investor Alert
• Negative Sentiment: Market reaction shows concern that large deals (Vivtex) and pipeline expansion may pressure near‑term margins and raise execution questions — some headlines explicitly note the stock dipped after the Vivtex announcement. Stock Dipped After Vivtex Deal

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $37.50 on Friday. The company’s fifty day moving average price is $52.75 and its 200-day moving average price is $52.85. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market capitalization of $167.42 billion, a price-to-earnings ratio of 10.81 and a beta of 0.67. Novo Nordisk A/S has a one year low of $37.31 and a one year high of $91.90.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.